{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=92",
    "query": {
      "intervention": "Placebo once daily",
      "page": 92
    },
    "page_size": 10
  },
  "pagination": {
    "page": 92,
    "page_size": 10,
    "total_count": 5521,
    "total_pages": 553,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=93&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=91&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:30:13.438Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01052428",
      "title": "Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mitral Regurgitation"
      ],
      "interventions": [
        {
          "name": "metoprolol succinate (Toprol XL)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 38,
      "start_date": "2004-08",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2012-11-22",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01052428"
    },
    {
      "nct_id": "NCT02778399",
      "title": "A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "OBE2109",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ObsEva SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 328,
      "start_date": "2016-07",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 71,
      "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02778399"
    },
    {
      "nct_id": "NCT03761030",
      "title": "L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Dysthymia",
        "Depression"
      ],
      "interventions": [
        {
          "name": "L-DOPA",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2019-01-09",
      "completion_date": "2021-09-08",
      "has_results": true,
      "last_update_posted_date": "2023-05-22",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761030"
    },
    {
      "nct_id": "NCT03316131",
      "title": "A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asymptomatic Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "Verinurad",
          "type": "DRUG"
        },
        {
          "name": "Febuxostat",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin matched placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-10-25",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316131"
    },
    {
      "nct_id": "NCT03592472",
      "title": "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Abexinostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Xynomic Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 413,
      "start_date": "2018-07-17",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Sacramento, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03592472"
    },
    {
      "nct_id": "NCT02442765",
      "title": "Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Agitation in Patients With Dementia of the Alzheimer's Type"
      ],
      "interventions": [
        {
          "name": "AVP-786",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 387,
      "start_date": "2015-07-23",
      "completion_date": "2019-02-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 111,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442765"
    },
    {
      "nct_id": "NCT01358162",
      "title": "Phase IC Study of Safety and PK of SQ109 300mg Daily",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "SQ109",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 10,
      "start_date": "2010-11",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2013-05-14",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358162"
    },
    {
      "nct_id": "NCT04937088",
      "title": "Outpatient Liquid Aspirin (OLA)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "ASA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center in New Orleans",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2021-12-06",
      "completion_date": "2022-12-05",
      "has_results": false,
      "last_update_posted_date": "2022-01-03",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04937088"
    },
    {
      "nct_id": "NCT00314782",
      "title": "Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ZD4054 (Zibotentan)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2006-03",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-12",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00314782"
    },
    {
      "nct_id": "NCT02255422",
      "title": "RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MItochondrial Myopathies"
      ],
      "interventions": [
        {
          "name": "Omaveloxolone capsules, 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 5 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 20 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 40 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 80 mg",
          "type": "DRUG"
        },
        {
          "name": "omaveloxolone capsules, 160 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2015-05-05",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-15T14:30:13.438Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02255422"
    }
  ]
}